lipodystrophy syndrome

lipodystrophy syndrome

AIDS A clinical state characterized by redistribution of fat, increased waist size, and loss of fatty tissue from the face, arms and legs, caused by protease inhibitors used to manage HIV-1-infected Pts Clinical Redistribution of fat Adverse effects N&V, maculopapular rash, headache, fatigue, headache, vertigo. See AIDS, Nonnucleoside reverse transcriptase inhibitor.

lipodystrophy syndrome

A side effect encountered in the treatment of HIV patients with protease inhibitors in which they develop abnormal accumulations of body fat (e.g., over the upper back), hypercholesterolemia, hyperglycemia, hypertriglyceridemia, and insulin resistance.

antiretroviral treatment-related lipodystrophy syndrome

HIV-related fat redistribution syndrome.

facial lipodystrophy syndrome

Facial lipoatrophy syndrome.
References in periodicals archive ?
The lipodystrophy syndrome is a well-recognised phenomenon in HIV-1-infected patients receiving antiretroviral therapy (ART).
Metabolic abnormalities and body fat redistribution in HIV infected patients: the lipodystrophy syndrome.
Clinical aspects of the lipodystrophy syndrome Fat accumulation * Abdominal obesity * Dorsocervical pad ('buffalo hump') * Cervical hypertrophy * Lipomas * Breast enlargement Fat loss * Face wasting (reduction or absence of subcutaneous tissue on the cheeks with sparing of the facial musculature) * Loss of subcutaneous fat of extremities * Loss of gluteal mass Biological abnormalities * Glucose intolerance, diabetes, hyperinsulinaemia and increased insulin resistance * Hypertriglyceridaemia * Hypercholesterolaemia: increased LDL cholesterol, decreased HDL cholesterol Table IV.
A report in AIDS by Andrew Carr and colleagues describes the physical and biochemical changes occurring in HIV-positive patients taking PIs, defining lipodystrophy syndrome for the first time.
Facial lipoatrophy, a component of the lipodystrophy syndrome, has now become the "scarlet letter of AIDS," said Dr.
There are very few studies addressing therapeutic strategies for HIV lipodystrophy syndrome.
Two-thirds of the HIV patients had a mixed lipodystrophy syndrome involving both the loss of subcutaneous fat and an increase in visceral far around the abdomen.
com/research/vf7jc5/hivassociated_lip) has announced the addition of Global Markets Direct's new report "HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H2 2012" to their offering.
The lipodystrophy syndrome is most commonly characterised by lipohypertrophy with lipomatosis.
Classical risk factors are metabolic abnormalities associated with insulin resistance and the lipodystrophy syndrome (visceral obesity, diabetes, dyslipidaemia) [61].
Treatment with antiretroviral agents--protease inhibitors in particular--has uncovered a syndrome of abnormal fat redistribution, dyslipidemia, and impaired glucose metabolism, collectively termed lipodystrophy syndrome.
The Australian Prevalence Survey of Lipodystrophy Syndrome is a large study involving 1350 patients followed between November 1998 and June 1999.